Get subscribed to our newsletter
Get interesting updates to your email inbox.
Bharat Biotech on Wednesday announced the first interim analysis of Covaxin, which shows the efficacy of the Covid-19 vaccine to be at 81 percent. The Hyderabad-based vaccine maker said the whole virion inactivated Covid-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 percent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research (ICMR).
“Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants.
Follow NewsGram on Facebook to stay updated.
Covaxin demonstrates a high clinical efficacy trend against Covid-19 but also significant immunogenicity against the rapidly emerging variants,” said Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech. BBV152 (Covaxin) contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells. It is stable at 2 to 8oC (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.
BBV152 has a 28-day open vial policy as a unique product characteristic, thus reducing vaccine wastage by approximately 10-30 percent, the vaccine maker said. BBV152 is based on an established manufacturing platform with a better safety profile when compared to other vaccine platforms. The inclusion of the Algel-IMDG adjuvant enhances T-cell immune responses to Covid-19, leading to long-term protection.
“I want to thank every one of the participants, who volunteered to participate in this vital clinical trial, our partners, principal investigators across 25 study sites, and our team at Bharat Biotech who dedicated their time to this vaccine discovery,” said Suchitra Ella, Joint Managing Director, Bharat Biotech.
The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of the Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) Covid-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.
The first interim analysis is based on 43 cases, of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the BBV152 group, resulting in a point estimate of vaccine efficacy of 80.6 percent. The interim analysis included a preliminary review of the safety database, which showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups.
The trial’s conduct and monitoring are as per Good Clinical Practice guidelines and have been outsourced to IQVIA. Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralize the UK variant strains and other heterologous strains, which has been published in bioRxiv.
Bharat Biotech expects to share further details of the trial results as additional data become available. Additional interim analysis is planned for 87 cases, and the final analysis is planned for 130 cases. All data from the second interim and final analyses will be shared via pre-publication servers as well as submitted to a peer-reviewed journal for publication, Bharat Biotech said. More than 40 countries globally have expressed their interest in Covaxin. These countries are highly satisfied with the safe, inactivated vaccine technology and robust data package for safety and immunogenicity, it added. (IANS/SP)
South Korea remained the No. 2 supplier of popular content to Netflix in the fourth quarter of last year, US online media have reported. According to What's On Netflix, a private online site that provides information on Netflix content, on Wednesday (US time), South Korean-made shows accounted for 11.8 per cent of the top 10 films and TV series in the final three months of 2021.
ALSO READ: Lessons Learnt From Squid Game
Korean content thus ranked No. 2 for the second consecutive quarter after the United States, which accounted for 59 per cent, reports Yonhap News Agency. The figures are based on data by the streaming analytics firm FlixPatrol, it added. It marked a sharp increase from its share of 5.4 per cent for the third quarter, thanks to the breakout hit 'Squid Game', released on September 17, and other hit series.
South Korean-made shows accounted for 11.8 per cent of the top 10 films and TV series in the final three months of 2021. | Unsplash
"The fourth quarter of 2021 is likely to be an outlier with the arrival of 'Squid Game', but Korean content has been on a slow march up the charts regardless of 'Squid Game'," the report said. 'Squid Game' became the most successful Netflix show in history, with its total viewership reaching a record 1.65 billion hours in the first four weeks of its release.
Two subsequent series, the fantasy horror 'Hellbound' and the sci-fi thriller 'The Silent Sea', also topped Netflix's official weekly viewership chart for non-English TV shows. (IANS/ MBI)
(Keywords: squid game, netflix, series, US, Korea, quarter, content, history viewership, hellbound, the silent sea, chart)
There has been a significant growth in adoption as well as deepening of digital payments across the country, showed the Reserve Bank of India - Digital Payments Index (RBI-DPI) on Wednesday. Accordingly, the index reading for September 2021 rose to 304.06 (index value) from 270.59 in March 2021. "The RBI-DPI Index continues to demonstrate significant growth in adoption and deepening of digital payments across the country," the RBI said in a statement.
Starting from March 2018, the index stood at 153.47 in March 2019, 173.49 in September 2019. This improved to 207.84 in March 2020, 217.74 in September 2020 and further increased to 270.59 in March 2021. Earlier, the RBI had announced construction of the composite index with March 2018 as a base to capture the extent of digitisation of payments across the country.
Starting from March 2018, the index stood at 153.47 in March 2019, 173.49 in September 2019. | Wikimedia Commons
The RBI-DPI comprises of five broad parameters that enable measurement of deepening and penetration of digital payments in the country over different time periods.Notably, these parameters are 'payment enablers', 'payment infrastructure -- demand side factors', 'payment infrastructure -- suppy side factors', 'payment performance' and 'consumer centricity'.Each of these parameters have sub-parameters which, in turn, consist of various measurable indicators. (IANS/ MBI)
(Keywords: adoption, payment, reserve bank of india, infrastructure, growth, march, index, digital, country, parameters)
After an embarrassingly slow start to the crypto new year, the tides of the crypto machine are starting to change and with it, the investors of Avalanche and HUH Token have received some rather spectacular rewards.
The cryptocurrency market this week saw value increases of over 20% and that’s enough to signal to any crypto investor that things are going better in the crypto sphere than last weeks value increase percentages, which, for the most part, were on a downtrend.
But with the spirits of the cryptocurrency community well and truly perked up, it’s no wonder that hungry crypto investors like yourself are looking for the next bonus round of value increases.
What’s So Special About Avalanche?
You might be wondering how two altcoins, like Avalanche and HUH Token, have popped up on your deep search of the crypto sphere and it’s for good reason … these two cryptocurrencies saw an exponential increase in value this week and with it, have driven the crypto community crazy with investment potential.
It seems like the crypto bug has been biting and the crypto sphere is regaining its pre-New Year vigour.
Avalanche the low-cost, eco-friendly programmable smart contracts platform saw an astonishing 3,042% from that point and investors are rejoicing at their before-the-curve investment in an altcoin.
Though if the numbers and investment trends of 2021 are anything to go off, altcoins like Avalanche and HUH Token are becoming the prefered crypto choice for whale investors.
HUH Token are making steps in this direction with their play-to-earn game launching in February.Dailyhodi
Not many currencies saw such a drastic increase of value like Avalanche, and aside from its forward-thinking, inclusive crypto technology, this is one of the abilities that make Avalanche special.
Its continuing growth potential.
Never Heard Of HUH Token, HUH?
Now, this might not be true for the seasoned crypto lover reading this article, however for those of you who are new to the crypto sphere, HUH Token is the altcoin trailblazer that launched a little over a month ago.
Also Read: Will SafeMoon Be Eclipsed By HUH Token?
HUH Token saw an incredible increase and is set to see more value rises over the next month with its 500 wide influencer launch, play-to-earn launch and dropping their presale holders NFTs on the 31st of January.
It’s events like these that often cause value spikes in altcoins and for that reason, HUH holders are more than thrilled with Utimeme.
HUH Token is the blend of blockchain technology and holder-centric values that most investors crave because it allows them to have greater input over what happens to their well-earned money.
Like Avalanche, HUH Token is a currency that wants to bring a new kind of crypto investor to the market, and that’s one from any kind of financial background… HUH Token are making steps in this direction with their play-to-earn game launching in February.
These are some of the reasons that a bonus round for those who missed out on the crypto windfall of January 1st investors, could be around the corner.
Remember, it’s always best to do your research into crypto before investing and you can begin your search by visiting the links below or going to Avalanche and HUH Token websites.
Disclaimer: (This article is sponsored and includes some commercial links)